CY1120358T1 - Μακροκυκλικα πολυμορφα, συνθεσεις που περιλαμβανουν τετοια πολυμορφα, μεθοδοι βιομηχανικης παρασκευης και χρησης εξ' αυτων - Google Patents
Μακροκυκλικα πολυμορφα, συνθεσεις που περιλαμβανουν τετοια πολυμορφα, μεθοδοι βιομηχανικης παρασκευης και χρησης εξ' αυτωνInfo
- Publication number
- CY1120358T1 CY1120358T1 CY20181100659T CY181100659T CY1120358T1 CY 1120358 T1 CY1120358 T1 CY 1120358T1 CY 20181100659 T CY20181100659 T CY 20181100659T CY 181100659 T CY181100659 T CY 181100659T CY 1120358 T1 CY1120358 T1 CY 1120358T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- staphylococcus
- polymorphoss
- polymorphos
- macrocyclic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 241000191940 Staphylococcus Species 0.000 abstract 3
- 241000193163 Clostridioides difficile Species 0.000 abstract 2
- 241000193468 Clostridium perfringens Species 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 241000194033 Enterococcus Species 0.000 abstract 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 abstract 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88195007P | 2007-01-22 | 2007-01-22 | |
| US11/831,886 US7378508B2 (en) | 2007-01-22 | 2007-07-31 | Polymorphic crystalline forms of tiacumicin B |
| PCT/US2008/000735 WO2008091554A1 (en) | 2007-01-22 | 2008-01-22 | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120358T1 true CY1120358T1 (el) | 2019-07-10 |
Family
ID=38661942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100659T CY1120358T1 (el) | 2007-01-22 | 2018-06-27 | Μακροκυκλικα πολυμορφα, συνθεσεις που περιλαμβανουν τετοια πολυμορφα, μεθοδοι βιομηχανικης παρασκευης και χρησης εξ' αυτων |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US7378508B2 (enExample) |
| EP (3) | EP2125850B1 (enExample) |
| JP (2) | JP5468388B2 (enExample) |
| KR (2) | KR20150006082A (enExample) |
| CN (2) | CN101663312B (enExample) |
| BR (1) | BRPI0806878A2 (enExample) |
| CA (2) | CA2676061C (enExample) |
| CY (1) | CY1120358T1 (enExample) |
| DK (1) | DK2125850T3 (enExample) |
| ES (2) | ES2821384T3 (enExample) |
| HR (1) | HRP20180912T1 (enExample) |
| HU (2) | HUE039395T2 (enExample) |
| IL (2) | IL199984A0 (enExample) |
| LT (1) | LT2125850T (enExample) |
| MX (2) | MX2009007730A (enExample) |
| NZ (2) | NZ578697A (enExample) |
| PL (2) | PL3412678T3 (enExample) |
| PT (2) | PT2125850T (enExample) |
| RU (1) | RU2478643C2 (enExample) |
| SI (1) | SI2125850T1 (enExample) |
| TR (1) | TR201810589T4 (enExample) |
| TW (2) | TWI425942B (enExample) |
| WO (1) | WO2008091554A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5113978B2 (ja) * | 2003-11-21 | 2013-01-09 | 味の素株式会社 | グルタミン酸誘導体の有機アミン塩及びその利用 |
| PL2070530T3 (pl) * | 2004-05-14 | 2016-06-30 | Merck Sharp & Dohme | Leczenie chorób związanych ze stosowaniem antybiotyków |
| US7906489B2 (en) | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US7935377B2 (en) * | 2004-06-04 | 2011-05-03 | Ajinomoto Co., Inc. | Crystals of free (2R, 4R)-monatin and use thereof |
| US7378508B2 (en) * | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| AU2008274941A1 (en) * | 2007-07-12 | 2009-01-15 | Tragara Pharmaceuticals, Inc. | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders |
| TWI523654B (zh) * | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
| EA027622B1 (ru) * | 2010-02-05 | 2017-08-31 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Твердофазные формы макроциклических ингибиторов киназы |
| PE20130308A1 (es) * | 2010-05-18 | 2013-04-06 | Optimer Pharmaceuticals Inc | Metodos para tratar infecciones bacterianas recurrentes |
| CA2826662A1 (en) * | 2011-02-04 | 2012-08-09 | Optimer Pharmaceuticals, Inc. | Treatment of bacterial infections |
| US20150157653A1 (en) * | 2012-03-16 | 2015-06-11 | Optimer Pharmaceuticals, Inc. | Prevention of Clostridium Difficile Infection in High Risk Patients |
| US8722863B2 (en) | 2012-05-10 | 2014-05-13 | Teva Pharmaceutical Works Ltd. | Solid state forms of fidaxomycin and processes for preparation thereof |
| JP2015516438A (ja) * | 2012-05-10 | 2015-06-11 | テヴァ・ファーマシューティカル・ワークス・リミテッド | フィダキソマイシンの固体状形態およびその調製方法 |
| JO3464B1 (ar) * | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
| EP2964196A1 (en) | 2013-03-08 | 2016-01-13 | Cipla Limited | Pharmaceutical compositions for rectal administration |
| CN103275152B (zh) * | 2013-05-29 | 2015-11-18 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度非达霉素的制备方法 |
| CN103275153B (zh) * | 2013-06-27 | 2016-03-23 | 华北制药集团新药研究开发有限责任公司 | 一种非达霉素晶体的制备方法 |
| CN104560766B (zh) * | 2013-10-16 | 2017-07-28 | 浙江海正药业股份有限公司 | 一种游动放线菌菌株及其应用 |
| US20150141356A1 (en) * | 2013-11-15 | 2015-05-21 | Optimer Pharmaceuticals, Inc. | Treatment of Clostridium Difficile Infection in High Risk Patients |
| US9862740B2 (en) | 2014-02-25 | 2018-01-09 | Olon S.P.A. | Process for preparing novel forms of tiacumicin B |
| WO2015127955A1 (en) | 2014-02-25 | 2015-09-03 | Olon S.P.A. | A new polymorph of tiacumicin b and process for preparation thereof |
| ES2668351T3 (es) | 2014-03-18 | 2018-05-17 | Xellia Pharmaceuticals Aps | Nuevos polimorfos y nuevos estados sólidos de tiacumicina B |
| US10137141B2 (en) | 2014-05-09 | 2018-11-27 | Astellas Pharma Europe Ltd. | Treatment regimen tiacumicin compound |
| WO2015175695A1 (en) * | 2014-05-13 | 2015-11-19 | Debrabander Jef | Small molecule compounds selective against gram-negative bacterial infections |
| CN104098637B (zh) * | 2014-07-09 | 2017-01-04 | 浙江海正药业股份有限公司 | 一种纯化非达霉素的方法 |
| MA41689A (fr) * | 2014-10-15 | 2017-08-22 | Bioxcel Corp | Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine |
| AU2016289307A1 (en) | 2015-07-03 | 2018-01-18 | Astellas Pharma Europe Ltd. | Novel dosage regimen tiacumicin compound |
| CN112190589A (zh) * | 2020-11-17 | 2021-01-08 | 首都医科大学附属北京胸科医院 | 非达霉素在制备抑制鸟分枝杆菌活性的产品中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1458512A (en) * | 1973-11-22 | 1976-12-15 | Lepetit Spa | Antibiotic substance |
| US4321362A (en) * | 1980-06-12 | 1982-03-23 | Eli Lilly And Company | De(mycinosyloxy)tylosin and process for its production |
| US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5583115A (en) | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| US5767096A (en) | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
| JP2000072760A (ja) | 1998-06-19 | 2000-03-07 | Ajinomoto Co Inc | 新規シストチアゾール類縁体 |
| JP2000053514A (ja) | 1998-08-06 | 2000-02-22 | Aquas Corp | レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法 |
| JP2000239266A (ja) | 1999-02-17 | 2000-09-05 | Ajinomoto Co Inc | 新規ポリエン系抗生物質 |
| DK1652926T3 (da) | 2000-04-28 | 2010-02-15 | Kosan Biosciences Inc | Krystallinsk epothilon D |
| AU2001211213A1 (en) | 2000-10-20 | 2002-04-29 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| CA2494742C (en) * | 2002-07-29 | 2015-05-12 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
| US20070105791A1 (en) | 2002-07-29 | 2007-05-10 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
| US7906489B2 (en) | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| PL2070530T3 (pl) * | 2004-05-14 | 2016-06-30 | Merck Sharp & Dohme | Leczenie chorób związanych ze stosowaniem antybiotyków |
| MX2007009196A (es) | 2005-01-31 | 2009-02-25 | Optimer Pharmaceuticals Inc | Compuestos macrocilicos de 18 miembros y analogos de los mismos. |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| JP2009512691A (ja) | 2005-10-21 | 2009-03-26 | オプティマー ファーマシューティカルズ，インコーポレーテッド | クロストリジウムディフィシレ関連の下痢の治療方法 |
| US20080176927A1 (en) | 2007-01-19 | 2008-07-24 | Optimer Pharmaceuticals, Inc. | Compositions of stable tiacumicins |
| ZA200905337B (en) | 2007-01-22 | 2010-10-27 | Optimer Pharmaceuticals Inc | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
| TWI523654B (zh) | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
-
2007
- 2007-07-31 US US11/831,886 patent/US7378508B2/en not_active Expired - Lifetime
-
2008
- 2008-01-22 SI SI200831973T patent/SI2125850T1/en unknown
- 2008-01-22 NZ NZ578697A patent/NZ578697A/xx unknown
- 2008-01-22 EP EP08713185.0A patent/EP2125850B1/en active Active
- 2008-01-22 KR KR1020147036325A patent/KR20150006082A/ko not_active Ceased
- 2008-01-22 US US12/523,790 patent/US8859510B2/en active Active
- 2008-01-22 LT LTEP08713185.0T patent/LT2125850T/lt unknown
- 2008-01-22 ES ES18167730T patent/ES2821384T3/es active Active
- 2008-01-22 HU HUE08713185A patent/HUE039395T2/hu unknown
- 2008-01-22 MX MX2009007730A patent/MX2009007730A/es active IP Right Grant
- 2008-01-22 JP JP2009546439A patent/JP5468388B2/ja active Active
- 2008-01-22 ES ES08713185.0T patent/ES2676308T3/es active Active
- 2008-01-22 HU HUE18167730A patent/HUE052444T2/hu unknown
- 2008-01-22 CA CA2676061A patent/CA2676061C/en active Active
- 2008-01-22 MX MX2013009811A patent/MX348083B/es unknown
- 2008-01-22 BR BRPI0806878-0A2A patent/BRPI0806878A2/pt not_active Application Discontinuation
- 2008-01-22 WO PCT/US2008/000735 patent/WO2008091554A1/en not_active Ceased
- 2008-01-22 EP EP18167730.3A patent/EP3412678B1/en active Active
- 2008-01-22 TW TW097102320A patent/TWI425942B/zh active
- 2008-01-22 CA CA2880860A patent/CA2880860A1/en not_active Withdrawn
- 2008-01-22 DK DK08713185.0T patent/DK2125850T3/en active
- 2008-01-22 PT PT87131850T patent/PT2125850T/pt unknown
- 2008-01-22 CN CN2008800091323A patent/CN101663312B/zh not_active Ceased
- 2008-01-22 KR KR1020097017476A patent/KR20090117924A/ko not_active Ceased
- 2008-01-22 TR TR2018/10589T patent/TR201810589T4/tr unknown
- 2008-01-22 PL PL18167730T patent/PL3412678T3/pl unknown
- 2008-01-22 PT PT181677303T patent/PT3412678T/pt unknown
- 2008-01-22 EP EP12156793A patent/EP2468761A1/en not_active Withdrawn
- 2008-01-22 NZ NZ601347A patent/NZ601347A/xx unknown
- 2008-01-22 PL PL08713185T patent/PL2125850T3/pl unknown
- 2008-01-22 RU RU2009131727/04A patent/RU2478643C2/ru active
- 2008-01-22 TW TW102129518A patent/TWI453015B/zh active
- 2008-01-22 CN CN2012101288303A patent/CN102746353A/zh active Pending
- 2008-01-22 HR HRP20180912TT patent/HRP20180912T1/hr unknown
- 2008-04-11 US US12/101,552 patent/US7863249B2/en active Active
-
2009
- 2009-03-04 US US12/397,686 patent/US8883986B2/en active Active
- 2009-07-21 IL IL199984A patent/IL199984A0/en unknown
-
2012
- 2012-06-07 IL IL220255A patent/IL220255A0/en unknown
-
2013
- 2013-03-15 US US13/839,299 patent/US20130252914A1/en not_active Abandoned
- 2013-07-22 JP JP2013151860A patent/JP5764168B2/ja active Active
-
2018
- 2018-06-27 CY CY20181100659T patent/CY1120358T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120358T1 (el) | Μακροκυκλικα πολυμορφα, συνθεσεις που περιλαμβανουν τετοια πολυμορφα, μεθοδοι βιομηχανικης παρασκευης και χρησης εξ' αυτων | |
| BRPI0619153B8 (pt) | derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica | |
| ECSP078052A (es) | Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas | |
| CL2004000732A1 (es) | Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer. | |
| MX339476B (es) | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. | |
| DK2164331T3 (da) | Borholdige små molekyler | |
| BRPI0809977A8 (pt) | Uso de um composto, compostos e composição farmacêutica que o contém | |
| UY28602A1 (es) | Compuestos quimicos | |
| Ng et al. | Combinatorial discovery process yields antimicrobial peptoids | |
| CU23464B7 (es) | (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| CL2004000849A1 (es) | Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras. | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| ATE473975T1 (de) | Chemische verbindungen | |
| ATE398613T1 (de) | Chemische verbindungen | |
| MX2016009230A (es) | Macrociclicos con grupos p2'heterociclicos como inhibidores del factor xia. | |
| PH12013501489A1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| UY28603A1 (es) | Compuestos quimicos | |
| CR9866A (es) | Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicoticos y neurodegenerativos | |
| ECSP088358A (es) | Tratamiento y profilaxis de microangiopatías | |
| UY28691A1 (es) | Derivados de difenilazetidona | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| CY1121284T1 (el) | Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων | |
| MX2014001600A (es) | 3,4-dihidro-1h-[1,8]naftiridinosas antibacterianas sustituidas con ciclopenta[c]pirrol. | |
| PH12021551058A1 (en) | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | |
| BR112022000041A2 (pt) | Inibidores de detecção de quorum e / ou metabólitos pósbióticos e métodos relacionados |